Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

UNIVERSAL IBOGAINE Engages Investor Relations Firm Blue Digital Media

V.IBO

(TheNewswire)

Universal Ibogaine Inc.

Calgary, AB – TheNewswire - June 13, 2022 Universal Ibogaine Inc. (TSXV:IBO), (OTC:IBOGF) and (FSE:JC4) (“UI” or the “Company”) a life sciences company with a mission to transform addiction treatment through the use of medicalized ibogaine and a global licensing model advises it has engaged investor communications firm Blue Digital Media & Web Solutions (“Blue Digital”) for assistance with expanding awareness of UI’s business activities.

Blue Digital will provide expanded distribution of the UI story across multiple channels and audiences. The expected result is increased awareness of UI’s plans for research into utilizing ibogaine as part of the delivery of a continuum of care treating opioid abuse and other addictions.

Blue Digital will receive compensation of USD 27,000 for a 3 month engagement effective June 13, 2022. In addition, Blue Digital will receive a total of 450,000 stock options to purchase common shares of the Company, with an exercise price of $0.10 per share, a term of 3 years to expiry, and vesting one-third at the end of each month of the term of service.

Nick Karos, UI’s Chief Executive Officer, noted “We are pleased to have access to Blue Digital’s distribution channels, as their reach across borders will expand awareness of our business to new audiences. Addiction knows no boundaries and so the solution we pursue must also be global in nature.”

About Universal Ibogaine Inc.

UI is a life sciences company, with a mission to transform addiction treatment using medicalized ibogaine through a planned Canadian clinical trial focused on opioid use disorder, and ultimately to utilize that protocol globally through planned future licensing agreements. UI is concurrently developing a state of the art holistic addiction treatment protocol at its Kelburn Recovery Centre that, when paired with the planned ibogaine detox protocol, is intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This news release may contain forward-looking statements and information. Forward-looking information is frequently characterized by words such ‎as "plans", "expect", "project", "intend", "will", "believe", "anticipate", "estimate", "scheduled", ‎‎"potential", or other similar words, or statements that certain events or conditions "may", "should" or ‎‎"could" occur. The forward-looking statements and information are based on certain key expectations ‎and assumptions made by UI. Although UI believes that the expectations and assumptions on which the forward-‎looking statements are based are reasonable, undue reliance should not be placed on the forward-‎looking statements because UI can give no assurance that they will prove to be correct.

Since ‎forward-looking statements address future events and conditions, by their very nature they involve ‎inherent risks and uncertainties. Actual results could differ materially from those currently anticipated ‎due to a number of factors and risks, which include, but are not limited to, risks that required ‎regulatory approvals are not obtained. The reader is cautioned that assumptions used in the ‎preparation of such information, although considered reasonable by UI at the time of ‎preparation, may prove to be incorrect and readers are cautioned not to place undue reliance on ‎forward-looking information, which speaks only to conditions as of the date hereof. UI does not ‎undertake any obligation to release publicly any revisions to forward-looking information contained ‎herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence ‎of unanticipated events, except as may be required under applicable securities laws. ‎

For further information:

Investor Relations: Dugan Selkirk, IR Manager

dugan.selkirk@universalibogaine.com

Related Links

https://universalibogaine.com

Copyright (c) 2022 TheNewswire - All rights reserved.



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today